EGFR and lung cancer: Osimertinib is a third‐generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI), which shows great efficacy in first‐line treatment of EGFR mutation‐positive advanced non‐small cell lung cancer (NSCLC).1